From “just live with it” to a new valve without open-heart surgery — how VDyne is rewriting the future of the heart’s forgotten valve.
Tricuspid regurgitation is the heart condition hiding in plain sight. The tricuspid valve sits on the right side of the heart, and when its leaflets stop closing properly, blood leaks backward with every beat, draining the body of energy and flooding it with fluid until the swelling, breathlessness, and exhaustion tip into heart failure. More than 1.5 million Americans live with clinically significant TR, and several million more with moderate-or-greater disease, yet fewer than 8,000 tricuspid valve operations are performed in the U.S. each year even though a moderate-to-severe leak carries a one-year death rate above 10%. For decades the only definitive fix was open-heart surgery most of these patients were too fragile to survive, so they were told to live with it.
VDyne, headquartered in Maple Grove, Minnesota, one of the country’s densest hubs of medical-device innovation, was founded to take on exactly that problem. The roughly 70-person clinical-stage company, an early winner of the ICI Worldwide Startup Competition’s Award for Innovation in Cardiology, built its technology hand-in-hand with leading structural heart physicians across the U.S., Europe, and Australia.
Its answer is TriNova, a transcatheter tricuspid valve replacement engineered from the ground up for the right side of the heart rather than adapted from left-heart devices. Using VDyne’s patented side-delivery technology, TriNova is threaded through a vein and seated inside the native valve, no chest incision, and is designed to work with the anatomy: six sizes to fit a wide range of patients, a design intended to spare the heart’s electrical system so far fewer patients need a new pacemaker, an integrated AV Port, compatibility with existing pacemaker leads, and no barbs or hooks. Patients can go home in days rather than months.
In July 2026, VDyne treated the first patient in TRIVITA, its U.S. IDE pivotal trial (NCT07516444) — a randomized, head-to-head study against the commercially available Edwards EVOQUE system, spanning up to 70 sites across the U.S. and Europe, alongside the ongoing VISTA U.S. and VISTA Global studies that have produced encouraging early data. (TriNova remains investigational and is not yet approved for commercial sale.) For the patients who’ve been told to just live with it, the families watching them fade, and the physicians searching for another option, this is the segment to watch.







